Daiichi Sankyo Europe’s Specialty portfolio focuses on cardiovascular care and generated revenues of more than 1bn EUR in the last fiscal year.

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today multiple data presentations at the European Atherosclerosis Society (EAS) Congress ...

--Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH, the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced today a $125 million ...

MUNICH, August 31, 2024--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by ...

Final Takeaway Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions.

Daiichi Sankyo Europe, DSE Europe have been factories, concerning this DXd-ADC capital investment has been made and we have expanded the production facilities and we would reinforce it.

Masahiro Kato returns to Europe from Japan, having spent several years already in the European headquarter organisation from 2003 to 2010. His 35 years at Daiichi Sankyo spans roles in Finance, ...

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO? in Europe, provides a 20% ...

– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and ...

His 35 years at Daiichi Sankyo spans roles in Finance, Accounting and most recently Sustainability Promotion, an increasingly important area for Daiichi Sankyo.